Abstract
The development of DNA-targeted next-generation platinum-based anticancer chemotherapeutics is often accompanied by studies on the reactivity to DNA models. However, the incubation conditions used in literature vary widely, and some of the buffer/salts used are known to form complexes with Pt. Such coordination can influence the binding process and also the adducts formed. In a systematic approach, studies on the binding of cisplatin (1 mM) to dGMP (2 mM) in a series of different incubation solutions of relevance to biological systems are reported, employing capillary zone electrophoresis (CZE) with UV/vis and electrospray ionization–mass spectrometric (ESI-MS) detectors. Kinetic experiments performed with CZE–UV showed a high reactivity of dGMP to cisplatin in pure water (τ 1/2 = 4.1 ± 0.7 h) but a significantly slowed down in a solution containing a carbonate/phosphate buffer supplemented with NaCl, resulting in a half-life of dGMP of 25 ± 3 h. Especially carbonate had a major impact on the binding, though no coordination to the metal center was detectable with the methods used. The only adducts containing buffer components were (phosphate)Pt and tris(ammine)Pt species, as identified by means of CZE–ESI-MS, in addition to the main adduct [Pt(NH3)2(dGMP)2 − 4H+]2− and other less abundant Pt-containing species.
Similar content being viewed by others
References
Rosenberg B, Van Camp L, Krigas T (1965) Nature 205:698–699
Galanski M (2006) Recent Pat Anti-Cancer Drug Disc 1:285–295
Wheate NJ, Walker S, Craig GE, Oun R (2010) Dalton Trans 39:8113–8127
Gibson D (2009) Dalton Trans 0:10681–10689
Todd RC, Lippard SJ (2009) Metallomics 1:280–291
Bell DN, Liu JJ, Tingle MD, Rattel B, Meyer TU, McKeage MJ (2008) Clin Exp Pharmacol Physiol 35:1440–1446
Allardyce CS, Dyson PJ, Coffey J, Johnson N (2002) Rapid Commun Mass Spectrom 16:933–935
Brauckmann C, Wehe C, Kieshauer M, Lanvers-Kaminsky C, Sperling M, Karst U (2013) Anal Bioanal Chem 405:1855–1864
Hall MD, Okabe M, Shen D-W, Liang X-J, Gottesman MM (2008) Annu Rev Pharmacol Toxicol 48:495–535
Jennerwein M, Andrews P (1995) Drug Metab Dispos 23:178–184
Ziehe M, Esteban-Fernandez D, Hochkirch U, Thomale J, Linscheid MW (2012) Metallomics 4:1098–1104
García Sar D, Montes-Bayón M, Blanco González E, Sierra LM, Aguado L, Comendador MA, Koellensperger G, Hann S, Sanz-Medel A (2009) Anal Chem 81:9553–9560
Pompella A, Visvikis A, Paolicchi A, Tata VD, Casini AF (2003) Biochem Pharmacol 66:1499–1503
Kasherman Y, Sturup S, Gibson D (2009) J Med Chem 52:4319–4328
Esteban-Fernandez D, Canas B, Pizarro I, Palacios MA, Gomez-Gomez MM (2007) J Anal At Spectrom 22:1113–1121
Reedijk J (2009) Eur J Inorg Chem 2009:1303–1312
Bosch ME, Sánchez AJR, Rojas FS, Ojeda CB (2008) J Pharm Biomed Anal 47:451–459
Polak M, Plavec J, Trifonova A, Foldesi A, Chattopadhyaya J (1999) J Chem Soc, Perkin Trans 1 0:2835–2843
Küng A, Strickmann DB, Galanski M, Keppler BK (2001) J Inorg Biochem 86:691–698
Hann S, Zenker A, Galanski M, Bereuter TL, Stingeder G, Keppler BK (2001) Fresenius J Anal Chem 370:581–586
Warnke U, Gysler J, Hofte B, Tjaden UR, van der Greef J, Kloft C, Schunack W, Jaehde U (2001) Electrophoresis 22:97–103
Warnke U, Rappel C, Meier H, Kloft C, Galanski M, Hartinger CG, Keppler BK, Jaehde U (2004) ChemBioChem 5:1543–1549
Garcia Sar D, Montes-Bayon M, Blanco Gonzalez E, Sanz-Medel A (2006) J Anal At Spectrom 21:861–868
Jung Y, Lippard SJ (2007) Chem Rev 107:1387–1407
Davies MS, Berners-Price SJ, Hambley TW (2000) Inorg Chem 39:5603–5613
Binter A, Goodisman J, Dabrowiak JC (2006) J Inorg Biochem 100:1219–1224
Park J-S, Kim SH, Lee N-K, Lee KJ, Hong S-C (2012) Phys Chem Chem Phys 14:3128–3133
Todd RC, Lovejoy KS, Lippard SJ (2007) J Am Chem Soc 129:6370–6371
Appleton TG, Berry RD, Davis CA, Hall JR, Kimlin HA (1984) Inorg Chem 23:3514–3521
Prenxler PD, McFadyen WD (1997) J Inorg Biochem 68:279–282
Centerwall CR, Goodisman J, Kerwood DJ, Dabrowiak JC (2005) J Am Chem Soc 127:12768–12769
Bytzek AK, Hartinger CG (2012) Electrophoresis 33:622–634
Hartinger CG, Keppler BK (2007) Electrophoresis 28:3436–3446
Klampfl CW (2009) Electrophoresis 30:S83–S91
Dhara SC (1970) Indian J Chem, Sect B 8:193–194
Basu A, Krishnamurthy S (2011) J Nucleic Acids 2011:16
Schluga P, Hartinger CG, Egger A, Reisner E, Galanski M, Jakupec MA, Keppler BK (2006) Dalton Trans 14:1796–1802
Zenker A, Galanski M, Bereuter TL, Keppler BK, Lindner W (2000) J Chromatogr B 745:211–219
Chottard JC, Girault JP, Chottard G, Lallemand JY, Mansuy D (1980) J Am Chem Soc 102:5565–5572
Song B, Oswald G, Bastian M, Sigel H, Lippert B (1996) Met Based Drugs 3:131–141
Grabmann G, Meier SM, Scaffidi-Domianello YY, Galanski M, Keppler BK, Hartinger CG (2012) J Chromatogr A 1267:156–161
Scovell WM, O’Connor T (1977) J Am Chem Soc 99:120–126
Østergaard J, Jorgensen L, Engelbrecht Thomsen A, Weng Larsen S, Larsen C, Jensen H (2008) Electrophoresis 29:3320–3324
Zorbas-Seifried S, Jakupec MA, Kukushkin NV, Grössl M, Hartinger CG, Semenova O, Zorbas H, Kukushkin VY, Keppler BK (2007) Mol Pharmacol 71:357–365
Acknowledgments
We would like to thank the University of Vienna for a PhD scholarship for G.G. within the doctoral program BioProMoTION (Bioactivity Profiling and Metabolism) and COST CM1105 and the Austrian Science Fund (FWF, project number I496-B11) for financial support. Verena Pichler is acknowledged for preparing cisplatin, and G.G would like to thank Samuel M. Meier and Alexander E. Egger for fruitful discussions.
Author information
Authors and Affiliations
Corresponding author
Additional information
This paper is dedicated to Professor Franz Dickert on the occasion of his 70th birthday.
Rights and permissions
About this article
Cite this article
Grabmann, G., Keppler, B.K. & Hartinger, C.G. A systematic capillary electrophoresis study on the effect of the buffer composition on the reactivity of the anticancer drug cisplatin to the DNA model 2′-deoxyguanosine 5′-monophosphate (dGMP). Anal Bioanal Chem 405, 6417–6424 (2013). https://doi.org/10.1007/s00216-013-6937-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00216-013-6937-7